Ensemble Therapeutics is putting its discovery engine to work on ultrarare diseases. The Cambridge, MA-based biotech will explore its rapidly growing library of 10 million macrocycles to see what it can whip up for Alexion's pipeline.
AstraZeneca is casting a wide net across industry and academia for its nearly all outsourced neuroscience unit, now looping in Tufts University's School of Medicine to help develop therapies for ailments like Alzheimer's and Parkinson's.
AstraZeneca has enlisted Tufts University's School of Medicine in its virtual campaign to develop new drugs in the neurosciences field.
Rexahn Pharmaceuticals signed an exclusive license agreement of an undisclosed amount with the University of Maryland in Baltimore for a novel cancer-drug delivery platform that makes use of nanotechnology.
WuXi PharmaTech and PRA believe they have a bright future in China together, and they've picked up the founding CEO of Theorem Clinical Research to lead them there.
Boston Scientific is working to join rivals Medtronic and Edwards Lifesciences on the European aortic valve market, and the company has reached out to another competitor to speed its way, signing a manufacturing agreement with Sorin for the Lotus valve.
Diagnostics outfit Corgenix is upping its stake in the contract manufacturing game, inking a deal with EDP Biotech to produce a colon cancer test.
German genomics contractor Blackfield locked up a deal with AstraZeneca, agreeing to provide its computational biology technology to help the drugmaker validate an in-development cancer therapy.
Theorem Clinical Research has inked a deal with Emergo Group, pooling their resources to provide regulatory consultation to makers of medical devices and in vitro diagnostics.
Following its marked growth over the past few years, New Jersey's Catalent is consolidating its drug delivery operation and teaming up with a drug developer to push a new influenza treatment forward.